Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 363 results for "pfizer"

New Phase 2 Results Show Investigational Compound Glasdegib Im...

NEW YORK--(BUSINESS WIRE)-- Today, Pfizer Inc. ( PFE ) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) ... Yahoo! Finance UK and Ireland, 1 hour ago
[x]  

2,797 images for pfizer

Ticker Report, 3 hours ago
American Banking News, 15 hours ago
Ticker Report, 5 hours ago
Cancer Therapy Advisor, 22 hours ago
PharmaVOICE, 1 day ago
FiercePharma, 3 days ago
Livemint.com, 4 days ago
CNBC, 1 day ago
BioPharma-Reporter.com, 5 days ago
Sydney Morning Herald, 21 hours ago
Pharmafile

IBM, Pfizer collaborate to utilize Watson for Drug Discovery to accelerate immuno-oncology research

IBM Watson Health and Pfizer Inc. announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight ...
 PharmaBiz17 hours ago IBM, Pfizer Announce Partnership (IBM, PFE)  Yahoo! Finance1 day ago Pfizer, IBM Watson in Immuno-oncology Research Pact  Contract Pharma1 day ago Pfizer teams up with IBM Watson Health in immuno-oncology  Pharmafile1 day ago
[x]  

Pfizer announces positive results from phase 3 study of Lyrica to treat paediatric epilepsy

Pfizer Inc. announced positive top-line results of a study that evaluated the use of Lyrica (pregabalin) capsules CV and oral solution CV as adjunctive therapy for paediatric epilepsy patients four to 16 years of age with partial onset seizures. ...
 PharmaBiz12 hours ago Lyrica Meets Key Efficacy Endpoint in Pediatric Epilepsy Trial  PT Community1 day ago Pfizer's Lyrica successful in late-stage study in pediatric epilepsy  Seeking Alpha2 days ago BRIEF-Pfizer's pain drug Lyrica meets goal in late-stage pediatric epilepsy study  Reuters UK2 days ago
[x]  
Motley Fool

Forget Pfizer: Here Are 3 Better Dividend Stocks

When people think dividend stocks, Pfizer ( NYSE:PFE ) is sure to be high on the list. After all, the massive pharma stock pays out 3.75% annually, solidly beating the S&P 500's yield of around 2%. And given that Pfizer only paid out 56% of its ...
 Motley Fool22 hours ago 5 Best Dividend Stocks To Buy Right Now  InsiderMonkey.com1 day ago 3 solid stocks that also pay juicy dividends  CBS News1 day ago
Zolmax News

Guggenheim neutral on Pfizer

Guggenheim initiates coverage on Pfizer ( PFE +0.5%) with a Neutral rating joining four other shops with like ratings (recent updates) and price targets between $33 - 38. Four other analysts who updated coverage this month rate it a Buy with price ...
 Seeking Alpha1 day ago Guggenheim Begins Coverage on Pfizer Inc. (PFE)  Zolmax News15 hours ago Pfizer Inc. (PFE) Coverage Initiated at Guggenheim  American Banking News15 hours ago
EuroInvestor

Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Seven infused participants who have progressed to at least 12 weeks post-vector administration as of Nov. 30, 2016 have a ...
 4 Traders4 hours ago
[x]  
CNBC

Trader Lebenthal, up 30% this year, makes Pfizer a top holding

| Trader Jim Lebenthal, whose "Halftime Report" model portfolio is up 30 percent this year, added Pfizer as one of this top holdings for the competition.
 CNBC1 day ago

Morgan Stanley: Chevron, Pfizer Will be Big Winners in 2017

Chevron and Pfizer will not just be big yielders in 2017, but big winners too, says Morgan Stanley's
 Yahoo! Finance1 day ago
DNA

Pfizer to discontinue popular Corex cough syrup; retain brand

Pfizer will be discontinuing its popular Corex cough syrup but will retain the 'Corex' brand for future line extensions, the pharmaceutical told the BSE in a notification on Tuesday. The decision was taken after comprehensive tests of its respiratory ...
 DNA4 days ago Pfizer withdraws Corex syrup, extends line to new products  Money Control4 days ago Pfizer provides business update  Business Standard4 days ago Pfizer to withdraw Corex syrup, extend line to new products  Business Line4 days ago

How Pfizer and IBM Are Teaming Up to Develop Next-Gen Cancer Drugs

Tech giant IBM ibm and flagship U.S. pharma Pfizer pfe this morning announced a wide-ranging new collaboration to help identify next-generation cancer treatments. Pfizer will be harnessing the power of IBM's Watson supercomputer ...
 Fortune2 days ago Pfizer and IBM's Watson Supercomputer Are Teaming Up to Develop Next-Gen Cancer Drugs  Fortune2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less